Imviva Biotech Advances CTA313 CAR-T Program with FDA IND Approval
BOSTON, June 9, 2026 Imviva Biotech announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
BOSTON, June 9, 2026 Imviva Biotech announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational...
BASEL, Switzerland, June 1, 2026 Novartis announced that it will present new data from 31 abstracts across its expanding...
BEIJING — May 28, 2026 InnoCare Pharma announced that China’s Center for Drug Evaluation (CDE) under the National Medical...
MISSISSAUGA, Ontario, May 22, 2026 Roche Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation...
BEIJING, April 29, 2026 InnoCare Pharma has announced that the first patient has been dosed in the registrational Phase...
SPRING HOUSE, Pa., March 3, 2026 Johnson & Johnson has received U.S. Food and Drug Administration (FDA) Fast Track...
